Pfizer Inc. provided earnings guidance for the financial year 2023. For the year, the company expected to reported revenue of $67.0 to $71.0 Billion, the revenues Excluding COVID-19 Products Expected to Grow 7% to 9% Operationally Compared to Full-Year 2022 and Revenue Guidance for Comirnaty of $13.5 Billion and Paxlovid of $8 Billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26 USD | +2.40% | +0.54% | -9.69% |
Apr. 17 | Sector Update: Health Care Stocks Retreating Late Afternoon | MT |
Apr. 17 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.69% | 144B | |
+24.60% | 672B | |
+24.08% | 550B | |
-5.63% | 351B | |
+15.37% | 317B | |
+7.38% | 292B | |
+3.26% | 211B | |
+0.78% | 203B | |
-6.63% | 141B | |
-3.20% | 113B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Pfizer Inc. Provides Earnings Guidance for the Financial Year 2023